420 related articles for article (PubMed ID: 32005356)
1. [Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?].
Debourdeau P; Cossou-Gbeto C; Takam-Sohwe T; Laroche JP
Bull Cancer; 2020 Feb; 107(2):224-233. PubMed ID: 32005356
[TBL] [Abstract][Full Text] [Related]
2. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
[TBL] [Abstract][Full Text] [Related]
4. Are direct oral anticoagulants an economically attractive alternative to low molecular weight heparins in lung cancer associated venous thromboembolism management?
Howlett J; Benzenine E; Fagnoni P; Quantin C
J Thromb Thrombolysis; 2020 Oct; 50(3):642-651. PubMed ID: 32020515
[TBL] [Abstract][Full Text] [Related]
5. [Cancer and venous thromboembolism recurrence: The keys for an optimal management].
Mahé I; Benhamou Y; Helfer H; Chidiac J
Bull Cancer; 2018 May; 105(5):508-516. PubMed ID: 29544692
[TBL] [Abstract][Full Text] [Related]
6. [Venous thrombo-embolic disease in cancer. Low molecular weight heparin indications].
Nou M; Laroche JP
J Mal Vasc; 2016 May; 41(3):197-204. PubMed ID: 27146099
[TBL] [Abstract][Full Text] [Related]
7. [New international guidelines for curative treatment and prophylaxis for venous thromboembolism (VTE) in cancer patients and the dedicated smartphone application].
Benzidia I; Connault J; Solanilla A; Michon-Pasturel U; Jamelot M; Nguessan MK; Hij A; Le Maignan C; Farge D; Frère C;
J Med Vasc; 2017 Dec; 42(6):375-383. PubMed ID: 29203044
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of cancer associated thrombosis].
Hindré R; Hamdan A; Pastré J; Planquette B; Sanchez O
Bull Cancer; 2022 May; 109(5):528-536. PubMed ID: 35063183
[TBL] [Abstract][Full Text] [Related]
9. The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients.
Lee AY
Curr Opin Pulm Med; 2003 Sep; 9(5):351-5. PubMed ID: 12904702
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
[TBL] [Abstract][Full Text] [Related]
11. Trousseau's syndrome: cancer-associated thrombosis.
Ikushima S; Ono R; Fukuda K; Sakayori M; Awano N; Kondo K
Jpn J Clin Oncol; 2016 Mar; 46(3):204-8. PubMed ID: 26546690
[TBL] [Abstract][Full Text] [Related]
12. [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
Auditeau C; Talbot A; Blandinières A; Smadja DM; Gendron N
Bull Cancer; 2020 May; 107(5):574-585. PubMed ID: 32252973
[TBL] [Abstract][Full Text] [Related]
13. Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study.
Sevestre MA; Belizna C; Durant C; Bosson JL; Vedrine L; Cajfinger F; Debourdeau P; Farge D;
J Mal Vasc; 2014 May; 39(3):161-8. PubMed ID: 24746736
[TBL] [Abstract][Full Text] [Related]
14. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
Pritchard ER; Murillo JR; Putney D; Hobaugh EC
J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
[TBL] [Abstract][Full Text] [Related]
15. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
Cosmi B
Expert Opin Pharmacother; 2021 Apr; 22(5):583-594. PubMed ID: 33243038
[No Abstract] [Full Text] [Related]
16. Prevention and treatment of cancer-associated thrombosis.
Ng S; Carrier M
Curr Oncol; 2020 Oct; 27(5):275-278. PubMed ID: 33173380
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.
Dranitsaris G; Shane LG; Woodruff S
J Oncol Pharm Pract; 2019 Jan; 25(1):68-75. PubMed ID: 28857713
[TBL] [Abstract][Full Text] [Related]
18. The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants.
Prandoni P
Expert Opin Pharmacother; 2015; 16(16):2391-4. PubMed ID: 26360919
[TBL] [Abstract][Full Text] [Related]
19. Management of venous thromboembolism in patients with cancer.
Noble S; Jenkins DA
Br J Hosp Med (Lond); 2009 Jul; 70(7):380-5. PubMed ID: 19584778
[TBL] [Abstract][Full Text] [Related]
20. [Venous thromboembolism and cancer].
Meyer G
Rev Prat; 2015 Feb; 65(2):216-9. PubMed ID: 25939227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
